相关实验视频

Updated: May 4, 2026

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Generation of Orthotopic Pancreatic Tumors and Ex vivo Characterization of Tumor-Infiltrating T Cell Cytotoxicity

Published on: December 7, 2019

揭示治疗潜力:在癌中发现TGFßR1的预后标志物和潜在抑制剂

Samvedna Singh¹, Himanshi Gupta¹, Subhav Sinha²

¹School of Biotechnology, Gautam Buddha University, Greater Noida, UP, India.

Computational biology and chemistry

|August 26, 2025

概括

胰腺癌研究发现了新的预后标志物和潜在的药物点. 针对TGF-β受体1的新化合物对未来的胰腺癌疗法具有前途.

科学领域:

癌症学
计算化学
分子生物学

背景情况:

胰腺癌的存活率很低,对化疗的耐药性也很低.
没有早期发现胰腺癌的标志物.
不同表达的基因 (AHNAK2,TSC2,LAMC2,C3orf52,IGFBP3) 与预后不佳有关.

研究的目的:

确定胰腺癌的新预后标志物.
研究向TGF-β信号通路的治疗潜力.
发现抑制TGFßR1的新型小分子.

主要方法:

不同基因表达分析和生存分析.
对TGFßR1进行基于结构的虚拟选.
分子动力学模拟和总体采样以分析结合机制.
与基准抑制剂 (Galunisertib,Vactosertib) 的结合自由能量的比较.

主要成果:

在胰腺癌中发现了SMAD4突变 (20. 93%),突出显示了TGF-β通路的相关性.
三种化合物 (化合物6,7,8) 根据药理动力和结合性而入围.
分子动力学发现关键残留物 (ASP351,LYS232,LYS337,LYS213) 对TGFßR1的稳定性至关重要.
入围化合物的自由能量 (ΔG) 比基准抑制剂低.

结论:

向TGF-β信号通路是胰腺癌的一个有前途的治疗策略.
通过虚拟查发现的新化合物显示为TGFßR1抑制剂的潜力.
了解TGFßR1结合机制为药物开发提供了洞察力.

关键词:

分子动态模拟胰腺癌预测标志物抑制TGF-β的作用转化生长因子β (TGF-β)总体采样

更多相关视频

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells

Published on: October 27, 2020

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies

Published on: September 15, 2023

相关概念视频

TGF - β Signaling Pathway

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...